- Home
- SPT vs CTMX Comparison
SPT vs CTMX Comparison
Compare SPT & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPT
- CTMX
- Stock Information
- Founded
- SPT 2010
- CTMX 2008
- Country
- SPT United States
- CTMX United States
- Employees
- SPT N/A
- CTMX N/A
- Industry
- SPT Computer Software: Prepackaged Software
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- SPT Technology
- CTMX Health Care
- Exchange
- SPT Nasdaq
- CTMX Nasdaq
- Market Cap
- SPT 687.5M
- CTMX 596.2M
- IPO Year
- SPT 2019
- CTMX 2015
- Fundamental
- Price
- SPT $10.39
- CTMX $3.23
- Analyst Decision
- SPT Buy
- CTMX Strong Buy
- Analyst Count
- SPT 10
- CTMX 5
- Target Price
- SPT $27.70
- CTMX $5.80
- AVG Volume (30 Days)
- SPT 1.3M
- CTMX 2.8M
- Earning Date
- SPT 11-05-2025
- CTMX 11-07-2025
- Dividend Yield
- SPT N/A
- CTMX N/A
- EPS Growth
- SPT N/A
- CTMX 263.20
- EPS
- SPT N/A
- CTMX 0.49
- Revenue
- SPT $430,795,000.00
- CTMX $141,100,000.00
- Revenue This Year
- SPT $13.14
- CTMX N/A
- Revenue Next Year
- SPT $11.85
- CTMX N/A
- P/E Ratio
- SPT N/A
- CTMX $6.67
- Revenue Growth
- SPT 14.79
- CTMX 18.01
- 52 Week Low
- SPT $10.33
- CTMX $0.40
- 52 Week High
- SPT $36.30
- CTMX $3.91
- Technical
- Relative Strength Index (RSI)
- SPT 29.86
- CTMX 52.39
- Support Level
- SPT $10.33
- CTMX $3.21
- Resistance Level
- SPT $11.64
- CTMX $3.50
- Average True Range (ATR)
- SPT 0.47
- CTMX 0.23
- MACD
- SPT 0.08
- CTMX -0.07
- Stochastic Oscillator
- SPT 4.14
- CTMX 7.43
About SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.